Ocut-2C cells

OCUT-2C (Osaka City University Thyroid-2C) is a human anaplastic thyroid carcinoma cell line established from a pleural effusion of an 81-year-old Japanese female patient. The line grows as an adherent monolayer. OCUT-2C harbors two clinically significant oncogenic mutations: BRAF p.Val600Glu (V600E) and PIK3CA p.His1047Arg (H1047R), reflecting the concurrent MAPK and PI3K/Akt pathway activation commonly observed in dedifferentiated and anaplastic thyroid carcinomas. The presence of both BRAF V600E and PIK3CA H1047R provides a clinically relevant model for studying resistance mechanisms and combination therapy strategies in anaplastic thyroid cancer.
OCUT-2C is applicable in studies of anaplastic thyroid carcinoma biology, BRAF V600E + PI3K H1047R co-mutation biology, MAPK/ERK and PI3K/Akt pathway signalling, targeted therapy evaluation (BRAF inhibitors, MEK inhibitors, PI3K/mTOR inhibitors), and combination therapy approaches. As an anaplastic thyroid carcinoma model from a Japanese patient, it is relevant for studying the aggressive, treatment-resistant biology characteristic of this malignancy with a very poor prognosis.